Kemoplat

Cisplatin

Features

KEMOPLAT (Cisplatin Injection) contains cisplatin, which is a heavy metal complex containing a centralatom of platinum surrounded by two chloride ions and two ammonia molecules in the cis position. It is chemically a cis isomer of diammine dichloro platinum (II). KEMOPLAT is a clear, colourless to pale yellow solution.

Dosage

Metastatic Testicular Tumors

The usual dose for the treatment of testicular cancer in combination with other approved chemotherapeutic agents is 20 mg/m2 I.V. daily for 5 days per cycle.

Metastatic Ovarian Tumors

The usual cisplatin dose for the treatment of metastatic ovarian cancer in combination with cyclophosphamide is 75-100 mg/m2 I.V. per cycle once every 4 weeks (Day 1).

The dose of cyclophosphamide when used in combination with cisplatin is 600 mg/m2 IV once every 4 weeks (DAY 1). For directions for the administration of cyclophosphamide, refer to the cyclophosphamide package insert. In combination therapy, cisplatin and cyclophosphamide are administered sequentially.

As a single agent cisplatin should be administered as 100 mg/m2 IV per cycle once every 4 weeks.

Advanced Bladder Cancer

Cisplatin should be administered as a single agent at a dose of 50-70 mg/m2 I.V. per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy. For heavily pretreated patients an initial dose of 50 mg/m2 per cycle repeated every 4 weeks is recommended.

Indications

Metastatic Testicular Tumors

In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures.

Metastatic Ovarian Tumors

In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin therapy.

Advanced Bladder Cancer

Cisplatin is indicated as a single agent for patients with transitional cell bladder cancer, which is no longer amenable to local treatments such as surgery and/or radiotherapy

Product Information

KEMOPLAT (Cisplatin Injection 1.0mg/ml) is available as 10ml and 50ml single dose vial containing 10 mg & 50 mg of cisplatin, respectively.

 

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory